Pyridylmethylthio derivatives as VEGF inhibitors: Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 4, 2011, Pages 1232-1235

  Tajima, Hisashi ^a,b   Honda, Takahiro ^a,b   Kawashima, Kenji ^a   Sasabuchi, Yoshimasa ^a   Yamamoto, Minoru ^a,b   Ban, Masakazu ^a,b   Okamoto, Kazuyoshi ^a   Inoue, Kenji ^a   Inaba, Takaaki ^a   Takeno, Yuriko ^a   Tsuboi, Takashi ^a   Tonouchi, Asaka ^a   Aono, Hiroyuki ^a,b  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

AMD; Cancer; CYP; Pyridylmethylthio; RA; VEGF

Indexed keywords

4 PYRIDYLMETHYLTHIO DERIVATIVE; BETAMETHASONE SODIUM PHOSPHATE; CYTOCHROME P450; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; RAT; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79851510531     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.071     Document Type: Article

References (26)

1. M. Shibuya Folia Pharmacol. Japonica 122 2003 498
2. H. Sone, Y. Kawakami, M. Sakauchi, Y. Nakamura, A. Takahashi, H. Shimano, Y. Okuda, T. Segawa, H. Suzuki, and N. Yamada Biochem. Biophys. Res. Commun. 281 2001 562
3. A. Kvanta, P.V. Algvere, L. Berglin, and S. Seregard Invest. Ophthalmol. Vis. Sci. 37 1996 1929
4. C. Bell, E. Lynam, D.J. Landfair, N. Janjic, and M.E. Wiles In Vitro Cell Dev. Biol. Anim. 35 1999 533
5. Y. Chen, C. Wiesmann, G. Fuh, B. Li, H.W. Christinger, P. McKay, A.M. de Vos, and H.B. Lowman J. Mol. Biol. 293 1999 865
6. Y.S. Lin, C. Nguyen, J.L. Mendoza, E. Escandon, D. Fei, Y.G. Meng, and N.B. Modi J. Pharmacol. Exp. Ther. 288 1999 371
7. L. Sun, C. Liang, S. Shirazian, Y. Zhou, T. Miller, J. Cui, J.Y. Fukuda, J.Y. Chu, A. Nematalla, X. Wang, H. Chen, A. Sistla, T.C. Luu, F. Tang, J. Wei, and C. Tang J. Med. Chem. 46 2003 1116
8. P.A. Harris, A. Boloor, M. Cheung, R. Kumar, R.M. Crosby, R.G. Davis-Ward, A.H. Epperly, K.W. Hinkle, R.N. Hunter 3rd, J.H. Johnson, V.B. Knick, C.P. Laudeman, D.K. Luttrell, R.A. Mook, R.T. Nolte, S.K. Rudolph, J.R. Szewczyk, A.T. Truesdale, J.M. Veal, L. Wang, and J.A. Stafford J. Med. Chem. 51 2008 4632
9. G. Bold, K.H. Altmann, F. Jorg, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, P. Furet, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, E. Masso, R. Roth, C. Schlachter, W. Vetterli, D. Wyss, and J. Wood J. Med. Chem. 43 2000 2310
10. G. Bold, K.H. Altmann, F. Jorg, M. Lang, P.W. Manley, P. Traxler, B. Wietfeld, J. Bruggen, E. Buchdunger, R. Cozens, S. Ferrari, F. Pascal, F. Hofmann, G. Martiny-Baron, J. Mestan, J. Rosel, M. Sills, D. Stover, E. Masso, R. Roth, C. Schlachter, W. Vetterli, D. Wyss, and J. Wood J. Med. Chem. 43 2000 3200
11. P.W. Manley, P. Furet, G. Bold, J. Brueggen, J. Mestan, T. Meyer, C.R. Schnell, and J. Wood J. Med. Chem. 45 2002 5687
12. P.M. Manley, G. Bold, J. Brüggen, G. Fendrich, P. Furet, J. Mestan, C. Schnell, B. Stolz, T. Meyer, B. Meyhack, W. Stark, A. Strauss, and J. Wood Biochim. Biophys. Acta, Proteins Proteomics 1697 2004 17
13. A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, L. Wang, J. Bready, J. Estrada, R. Cattley, S. Kaufman, D. Chen, Y. Gan, G. Kumar, J. Meyer, S. Neervannan, G. Alva, J. Talvenheimo, S. Montestruque, A. Tasker, V. Patel, R. Radinsky, and R. Kendall Cancer Res. 66 2006 8715
14. T. Honda, H. Tajima, Y. Kaneko, M. Ban, T. Inaba, Y. Takeno, K. Okamoto, and H. Aono Bioorg. Med. Chem. Lett. 18 2008 2939
15. H. Tajima, T. Honda, K. Kawashima, Y. Sasabuchi, M. Yamamoto, M. Ban, K. Okamoto, K. Inoue, T. Inaba, Y. Takeno, and H. Aono Bioorg. Med. Chem. Lett. 20 2010 7234
16. Bohlmann, R.; Haberey, M.; Huth, A.; Ince, S. J.; Krueger, M.; Thierauch, K.-H.; Hess-Stumpp, H.; US Patent/US 7572794, 2005.
17. C.G. Wermuth The Practice of Medicinal Chemistry 2nd ed. 1990 Elsevier Chapter 30
18. S.A. Laufer, G.K. Wagner, D.A. Kotschenreuther, and W. Albrecht J. Med. Chem. 46 2003 3230
19. T. Shi, C. Lia, S.P. O'Connora, J. Zhang, M. Shi, S.N. Bisahaa, Y. Wanga, D.S. Sitkoffa, A.T. Pudzianowskia, C. Huanga, H.E. Kleia, K. Kisha, J. Yanchunas Jr., E.C.K. Liua, K.S. Hartla, S.M. Seilera, T.E. Steinbachera, A.W. Schumachera, K.S. Atwala, and P.D. Steina Bioorg. Med. Chem. Lett. 19 2009 6882
20. T. Annie, T. Fong, L.K. Shawver, L. Sun, C. Tang, H. App, T.J. Powell, Y.H. Kim, R. Schreck, X. Wang, W. Risau, A. Ullrich, K.P. Hirth, and G. McMahon Cancer Res. 59 1999 99
21. HUVEC was cultured into collagen coated well plate. After 1 day of incubation, VEGF and a test compound were added. After 3 days of incubation, cell number was counted. Compared with control, cell growth rate was calculated; see also Supplementary data.
22. M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D.J. Hicklin Cancer Res. 59 1999 5209
23. B16 cell suspension was sc injected into the C57BL/6 mouse (female, six weeks old) under anesthesia. The suspension of a test compound was administrated orally once a day every day. Ten days after injection, the weight of extirpated tumor tissue was measured. Compared with control, anti-cancer effect was calculated; see also Supplementary data.
24. The adjuvant was injected subcutaneously into a left hind paw sole of Lewis rats (male, nine weeks old) to induce arthritis. The suspension of a test compound was administrated orally once a day every day. Twenty one days after induction, the paw volume was measured. Paw edema inhibition rate was calculated and compared with control; see also Supplementary data.
25. X. Xianjin, N. Ogata, M. Komada, C. Yamamoto, K. Takahashi, K. Omori, and M. Uyama Graefes Arch. Cli. Exp. Ophthalmol. 235 1997 313
26. Under anesthesia and mydriasis, photocoagulation was performed in a Bruch's membrane of Brown Norway rats (male, eight weeks old) with a krypton laser. The suspension of a test compound was administrated orally once a day every day. Seven days after photocoagulation, fluorescein solution was injected into a tail vein. After fluorescein fundus photography was performed, fluorescence leak was counted. Neovascularization incidence rate was calculated and compared with control; see also Supplementary data.